Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 2, 2010, Pages 755-768

  Elnagar, Ahmed Y ^a   Wali, Vikram B ^a   Sylvester, Paul W ^a   El Sayed, Khalid A ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

3D QSAR; Anti invasive; Antiproliferative; Breast cancer; Carbamoylation; CoMFA; CoMSIA; Etherification; Redox silent; Tocotrienols; Vitamin E

Indexed keywords

2,5,7,8 TETRAMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL 4'' CHLOROPHENYLSULFONYLCARBAMATE; 2,5,7,8 TETRAMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL BENZOYLCARBAMATE; 2,5,7,8 TETRAMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL BENZYLCARBAMATE; 2,5,7,8 TETRAMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL PHENYLCARBAMATE; 2,5,7,8 TETRAMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL PHENYLSULFONYLCARBAMATE; 2,5,7,8 TETRAMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL TOSYLCARBAMATE; 2,7,8 TRIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL 4'' CHLOROPHENYLSULFONYLCARBAMATE; 2,7,8 TRIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL BENZOYLCARBAMATE; 2,7,8 TRIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL BENZYLCARBAMATE; 2,7,8 TRIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL PHENYLCARBAMATE; 2,7,8 TRIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL PHENYLSULFONYLCARBAMATE; 2,7,8 TRIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL TOSYLCARBAMATE; 2,8 DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL 4'' CHLOROPHENYLSULFONYLCARBAMATE; 2,8 DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL BENZOYLCARBAMATE; 2,8 DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL NAPHTHALEN 1'' YLCARBAMATE; 2,8 DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL PHENYLCARBAMATE; 2,8 DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL PHENYLSULFONYLCARBAMATE; 2,8 DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL TOSYLCARBAMATE; ALIPHATIC COMPOUND; ALKENE DERIVATIVE; ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOTRIENOL; ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; BETA TOCOTRIENOL; CARBAMIC ACID DERIVATIVE; DIMETHYL 2 (4',8',12' TRIMETHYLTRIDECA 3',7',11' TRIENYL)CHROMAN 6 YL BENZYLCARBAMATE; ETHER DERIVATIVE; GAMMA TOCOTRIENOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CELL ASSAY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ELECTRICITY; HUMAN; HUMAN CELL; HYDROGEN BOND; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASM INVASIVENESS; OXIDATION-REDUCTION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM; TOCOTRIENOLS;

EID: 76449106789     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.11.054     Document Type: Article

References (37)

1. Sen C.K., Khanna S., Roy S., and Packer L. J. Biol Chem. 275 (2000) 13049
2. Crowell P.L., Chang R.R., Ren Z.B., Elson C.E., and Gould M.N. J. Biol. Chem. 266 (1991) 17679
3. Elson C.E., and Yu S.G. J. Nutr. 124 (1994) 607
4. McIntyre B., Briski K.P., Gapor A., and Sylvester P.W. Proc. Soc. Exp. Biol. Med. 224 (2000) 292
5. Sporn M.B., and Suh N. Nat. Rev. Cancer 2 (2002) 537
6. Shukla S., and Gupta S. Nutr. Cancer 53 (2005) 18
7. Nesaretnam K., Guthrie N., Chambers A.F., and Carroll K.K. Lipids 30 (1995) 1139
8. Qureshi A.A., Sami S.A., Salser W.A., and Khan F.A. Atherosclerosis 161 (2002) 199
9. Khanna S., Roy S., Ryu H., Bahadduri P., Swaan P.W., and Ratan R.R. J. Biol. Chem. 278 (2003) 43508
10. Akaho N., Takata J., Fukushima T., Matsunaga K., Hattori A., Hidaka R., Fukui K., Yoshida M., Fujioka T.R., Karube Y., and Imai K. Drug Metab. Dispos. 35 (2007) 1502
11. Takata J., Hidaka R., Yamasaki A., Hattori A., Fukushima T., Tanabe M., Matsunaga K., Karube Y., and Imai K. J. Lipid Res 43 (2002) 2196
12. Mazzini F., Netscher T., and Salvadori P. Eur. J. Org. Chem. 13 (2009) 2063
13. Tomic-Vatic A., EyTina J., Chapman J., Mahdavian E., Neuzil J., and Salvatore B. Int. J. Cancer 117 (2005) 188
14. Kashiwagi K., Harada K., Yano Y., Kumadaki I., Hagiwara K., Takebayashi J., Kido W., Virgona N., and Yano T. Biochem. Biophys. Res. Commun. 365 (2008) 875
15. Ali H., and Nazzal S. J. Pharm. Biomed. Anal. 49 (2009) 950
16. Ohnmacht S., West R., Simionescu R., and Atkinson J. Magn. Reson. Chem. 46 (2008) 287
17. Shah S.J., and Sylvester P.W. Exp. Biol. Med. 230 (2005) 235
18. Liu, H.-K.; Wang, Q.; Li, Y.; Sun, W.-G.; Liu, J.-R.; Yang, Y.-M.; Xu, W.-L.; Sun, X.-R.; Chen, B.-Q., J. Nutr. Biochem., in press. doi:10.1016/j.jnutbio.2008.11.004).
19. Chang P., Yap W., Lee W.D., Ling M.T., Wong Y.C., and Yap Y. Nutr. Cancer 61 (2009) 357
20. Yap W.N., Chang P.N., Han H.Y., Lee D.T.W., Ling M.T., Wong Y.C., and Yap Y.L. Br. J. Cancer 99 (2008) 1832
21. Tamilarasan K.P., Kolluru G.K., Rajaram M., Indhumathy M., Saranya R., and Chatterjee S.B.M.C. Cell Biol. 7 (2006) 17
22. Borghesani P.R., Peyrin J.M., Klein R., Rubin J., Carter A.R., Schwartz P.M., Luster A., Corfas G., and Segal R.A. Development 6 (2002) 1435
23. Kubinyi H. In: Wolff M.E. (Ed). Burger's Medicinal Chemistry. 5th ed. Vol. I (1995), Wiley, New York 497-571
24. Arya P., Alibhai N., Qin H., Batist G., You S., and Alaoui-Jamali M. Bioorg. Med. Chem. Lett. 8 (1998) 2433
25. Pearlman R.S. 3D QSAR in Drug Design. Theory, Methods, and Applications (1993), ESCOM Science, Leiden, The Netherlands
26. El Sayed K., Khanfar M., Shallal H., Muralidharan A., Awate B., Youssef D., and Shah G. J. Nat. Prod. 71 (2008) 396
27. Pearce B., Parker R., Deason M., Qureshi A., and Wright K. J. Med. Chem. 35 (1992) 3595
28. Denizot F., and Lang R. J. Immunol. Methods 89 (1986) 271
29. Kleinman H.K., and Martin G.R. Semin. Cancer Biol. 15 (2005) 378
30. Koblinski J.E., Kaplan-Singer B.R., van Osdol S.J., Wu M., Engbring J.A., Wang S., Goldsmith C.M., Piper J.T., Vostal J.G., Harms J.F., Welch D.R., and Kleinman H.K. Cancer Res. 65 (2005) 7370
31. Gupte A., and Buolamwini J. Bioorg. Med. Chem. Lett. 19 (2009) 314
32. Viswanadhan V.N., Ghose A.K., Revankar G.R., and Robins R.K. J. Chem. Inf. Comput. Sci. 29 (1989) 163
33. Wold S., Rhue A., Wold H., and Dunn W.J. SAIM J. Sci. Stat. Comput. 5 (1994) 735
34. Wold S., Albano C., Dunn III W.J., Edlund U., Esbensen K., Geladi P., Hellberg S., Johanson E., Lindberg W., and Sjostrom M. NATO Sci. Ser., Ser. C 138 (Chemometrics) (1984) 17
35. Nikolic K., and Agababa D. J. Mol. Graph. Model. 27 (2009) 777
36. Nikolic K. J. Mol. Graph. Model 26 (2008) 868
37. Matter H., Will D., Nazare M., Schreuder H., Laux V., and Wehner V. J. Med. Chem. 48 (2005) 3290